Surmount · investment strategy
by Quantbase · via Surmount
Invests in companies revolutionizing healthcare through gene editing, personalized medicine, and advanced diagnostics. Rebalanced monthly, this strategy targets long-term growth in biotech, life sciences, and the future of medicine.
Description from Surmount
of the return and risk figures:as the source publishes them
What $10,000 would have become, from the strategy's own published history, against the S&P 500 over the same dates. The basis is labelled.
Each rule is quoted word for word from the strategy's own documents.
“Invests in companies revolutionizing healthcare through gene editing, personalized medicine, and advanced diagnostics”
“Rebalanced monthly”
28 positions as of 2026-10-20
by the source.
Top 25 of 28 shown.
Fitted to 68 returns (model) from 2026-04-08 to 2026-10-19. An estimate, not holdings: it can't name stocks.
· : 0.43 · Too loose a fit for a verdict; shown as a guide.
Beta to the S&P 500: 0.82 (90%: 0.24 to 1.04)
Compares the stated rules with the holdings (or, where none are published, a mix estimated from returns), using tests fixed before any results were seen.
0.0% of weight in (IVV: 3.0%)
2 funds (SEC N-PORT, as of 2026-07-31)
No stated fossil-fuel rule; the exposure is shown for reference. : 100% · 2026-10-20
0.0% of weight in (SPY: 0%)
Fewer than 70% of the holdings could be identified, so there’s no verdict. : 37% · 2026-10-20
How much of what we look for this strategy has, and why anything is missing. Fields that don't apply to it aren't counted.
1 missing
Rebalance schedule taken from a stated rule.
The text the rules are quoted from, with where it came from.
Invests in companies revolutionizing healthcare through gene editing, personalized medicine, and advanced diagnostics. Rebalanced monthly, this strategy targets long-term growth in biotech, life sciences, and the future of medicine.
Invests in companies developing genomics & precision medicine solutions
Invests in companies revolutionizing healthcare through gene editing, personalized medicine, and advanced diagnostics. Rebalanced monthly, this strategy targets long-term growth in biotech, life sciences, and the future of medicine.
Every value on file, each labelled with its calculation basis and as-of date.
| Asset classes / instruments | equity | 2026-10-20 |
| Minimum investment | $100 | 2026-10-20 |
| Industry weights (Surmount) | Healthcare: 96.8% · Financial Services: 3.2% | 2026-10-20 |
| Investors following (Surmount) | 3 | 2026-10-20 |
| Annual return (Surmount tracking) (model tracking) | 0.83% | ||
| Return, 3 months (Surmount tracking) (model tracking) | 16.78% | 2026-10-20 | |
| Total return (Surmount tracking) (model tracking) | 4.21% |
| Maximum drawdown (Surmount tracking) (model tracking) | -46.67% |
| Risk score (Surmount) | 3.38 | 2026-10-20 |
